Reagent Shop Altogen Begins Looking to Apply Technologies to Therapeutic siRNA Delivery | GenomeWeb

By Doug Macron

Looking to extend the use of its research products into the therapeutics field, Altogen Biosystems has begun exploring whether its transfection technologies can be used to deliver siRNA-based drugs, RNAi News has learned.

When it comes to research, "each of our customers has their own focus for delivery, [whether it] be siRNAs, microRNAs, [or] antibodies, and we offer the tools," Andreas Kim, vice president of research and development at Altogen, said this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.